InDex to Present Positive Results of Kappaproct for Ulcerative Colitis at Digestive Disease Week Meeting

InDex to Present Positive Results of Kappaproct for Ulcerative Colitis at Digestive Disease Week Meeting
InDex Pharmaceuticals today presents positive results of its lead drug candidate Kappaproct (cobitolimod) to treat moderate to severe active ulcerative colitis (UC) during the Digestive Disease Week congress now underway in Chicago. The Swedish company said in a press release that it is presenting two posters showing that the drug induces remission of UC symptoms. Kappaproct (cobitolimod) binds to the toll-like receptor 9 (TLR9), which enhances its function and leads to production of anti-inflammatory cytokines which help reduce inflammation and heal mucosal wounds. TLR9 is crucial in protection against intestinal damage and for intestinal repair. The first poster, “Binding properties of human TLR-9 receptor to cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development,"  shows the binding affinity of cobitolimod to TLR9. The second, “IL-10 induction properties of the TLR-9 agonist cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development," shows that the drug can induce a dose-dependent release in vitro of the anti-inflammatory cytokine IL-10 from immune cells obtained from both healthy individuals and UC patients. The COLLECT (
Subscribe or to access all post and page content.